DUBLIN – First-year results from a partnership between Medtronic and UnitedHealthcare show that use of Medtronic’s MiniMed 630G insulin pump reduced preventable hospital admissions for people with diabetes by 27%.
The partner study included more than 6,000 UnitedHealthcare members with diabetes who used standalone pumps and pumps integrated with continuous glucose monitors, as well as members who are on multiple daily injections of insulin. “These positive results provide further evidence of the benefits of both automated insulin delivery and of value-based healthcare models” said Hooman Hakami, executive vice president and president of the Diabetes Group at Medtronic, in a statement. “Through this unique partnership, Medtronic and UnitedHealthcare have demonstrated a commitment by both organizations to prioritize innovation that improves health outcomes and lowers healthcare costs.”
In 2016, UnitedHealthcare and Medtronic announced an expanded relationship that gave UnitedHealthcare members with diabetes access to advanced insulin pump technologies and comprehensive support services offered by Medtronic. These offerings currently include the company’s most advanced MiniMed 670G hybrid closed-loop system featuring SmartGuard technology and Guardian Sensor 3, which automates the delivery of a personalized amount of basal insulin every five minutes based on real-time sensor glucose values.
“Our hope is that this agreement is just the beginning and that the entire health care community follows UnitedHealthcare’s lead to not only champion innovation in diabetes that has a clear and measurable tie to better outcomes and lower cost, but to also drive business models that reward those results as they are achieved,” said Hakami.
The results reflect the first year of a multiyear initiative between UnitedHealthcare and Medtronic. Both quality of care and cost will continue to be evaluated over the duration of the relationship, providing additional opportunities for more people enrolled in UnitedHealthcare plans to better manage their diabetes and for quality care to be delivered in a more cost-effective manner.
“These results show that patients with diabetes can benefit from using insulin pumps and comprehensive support services, thereby increasing the quality of the care they receive and reducing hospital admissions, as well as costs,” said Dr. Peter Pronovost, chief medical officer at UnitedHealthcare, in a statement. “The first-year results are encouraging, and we will monitor patients using Medtronic pump therapies to ensure we continue to see improved quality of care, fewer hospitalizations, and lower costs.”